Nano‑X Imaging Ltd. (NASDAQ: NNOX) announced that its U.S. subsidiary, Nanox Impact Inc., has entered into a distribution agreement with Digital X‑Ray Imaging Inc. (DXI). Under the deal, DXI will market, install, and support the Nanox.ARC, a multisource digital tomosynthesis system that delivers 3‑D imaging at lower cost and reduced radiation dose compared with conventional CT. The partnership covers DXI’s regional network of major health systems in the Little Rock area and other Arkansas facilities.
The agreement marks Nano‑X’s fourth U.S. distribution collaboration in 2026, following deals with Integrity Medical Service, Elite Surgical Technologies, and Imperial Imaging Technology. By adding DXI to its channel roster, Nano‑X aims to accelerate deployment of the Nanox.ARC and broaden its market reach in a key U.S. state. DXI’s three‑decade track record serving hospitals, orthopedic practices, and outpatient clinics in Arkansas positions it to extend the product’s footprint quickly.
The Nanox.ARC is FDA‑cleared for general use, with the Nanox.ARC X receiving 510(k) clearance in April 2025 and the TAP2D cloud‑enabled image‑enhancement capability cleared in February 2026. The system’s proprietary cold‑cathode X‑ray source and compact footprint enable 3‑D imaging without the infrastructure burden of a full CT suite, offering a cost‑effective alternative for many clinical scenarios.
Erez Meltzer, CEO and Acting Chairman of Nano‑X, said, “Expanding our U.S. channel partner network with experienced, regionally dominant distributors is a core pillar of our commercial execution strategy, as we continue to advance the long‑term goal for adoption of digital tomosynthesis as a primary imaging option.” Drew Baxter, President of Digital X‑Ray Imaging, added, “The Nanox.ARC offers a practical solution for providers seeking access to 3‑D imaging when CT may be clinically unnecessary, without the cost and infrastructure burden of traditional CT systems.” The partnership underscores Nano‑X’s focus on scaling its digital tomosynthesis platform and strengthening its presence in the U.S. market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.